Author: ALLISON GATLIN
Source
Revance is reversing course to stay competitive with AbbVie’s aesthetics drug, Botox — and RVNC stock crashed Tuesday in response.
The post Former IBD 50 Stock Revance Implodes As Its ‘Prestige’ Plan Goes Up In Smoke appeared first on Investor’s Business Daily.